Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders 2026 Cheng et al

[Jaybee00]

https://www.nejm.org/doi/full/10.10...=featured_secondary_home#core-collateral-info
Abstract
Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. Paywalled.

https://www.nejm.org/doi/full/10.1056/NEJMc2603114

 

[Jaybee00]

“B-cell depletion, rebooting the immune system, is emerging as potentially curative for some refractory autoimmune diseases.
But that has mainly relied on complicated, time-consuming, laborious ex vivo (outside the body) methods.
Today @NEJM all 16 patients with refractory autoimmune neurologic conditions, including 7 with progressive multiple sclerosis, had clinical and biologic improvement with single dose in vivo (inside the body, off-the shelf lentivirus vector) B cell depletion.”

Hard to see the clinical outcome measures.